VentriJect
Overview
VentriJect is a Danish MedTech startup known for its innovative approach to measuring cardiorespiratory fitness (CRF). Established in 2018 as a spinout from Aalborg University, VentriJect focuses on developing non-wearable devices that employ seismocardiography to accurately estimate VO2 max without exercise. The company, headquartered in Copenhagen, Denmark, has raised approximately €1.7 million as of its latest funding round in August 2025. The startup was co-founded by Mikkel Kristiansen, Kasper Sørensen, Samuel Emil Schmidt, and Peter Boman Samuelsen.
Recent Developments
- August 2025: VentriJect secured €1.7 million in funding, primarily from existing investors such as the Export and Investment Fund of Denmark (EIFO) and other venture capitalists. This fundraising aims to expand the company’s market reach, particularly in the EU and potential entry into the US market.
- The investments will support enhancements in their signature Seismofit® device, facilitating wider distribution across Europe and exploring the American market.
- Anders Throup-Jensen from EIFO highlighted the company's leadership potential in the VO2 max measurement market, expressing confidence in their continued expansion.
- 2025: VentriJect is in final negotiations with numerous healthcare providers across Europe to expand its product's reach within the healthcare system.
- Distributors have been secured in Denmark, the Netherlands, Sweden, Switzerland, and the UK.
- Entering the US market remains a priority due to its large healthcare opportunities and numerous fitness centers.
- January 2025: Marylebone Health, a leading health performance clinic, adopted VentriJect's Seismofit® technology for VO2 max testing, demonstrating its integration into clinical settings without the need for traditional exercise-based testing.
- VentriJect's participation in various scientific forums and healthcare innovation competitions, including a prestigious recognition at the Healthcare Innovation World Cup, underscores its growing reputation in the MedTech landscape.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2018 |
| Headquarters | Copenhagen, Denmark |
| Founders | Mikkel Kristiansen, Kasper Sørensen, Samuel Emil Schmidt, Peter Boman Samuelsen |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Export and Investment Fund of Denmark, Investo Capital, TechStation |
| Industry | Medical Device Manufacturing |
| Number of Employees | Approximately 8 as of 2025 |
Early History
VentriJect began its journey in 2018 as a research project at Aalborg University in Denmark. The development was spearheaded by Kasper Sørensen and Samuel Emil Schmidt, who focused on creating a more accessible measurement system for cardiorespiratory fitness, a crucial health metric. By leveraging their expertise in cardio mechanics and seismocardiography, they co-developed the Seismofit® system, a non-exercise approach to estimating VO2 max, vital for hospital evaluations and fitness assessments. The founders' ambition was to simplify CRF measurement, making it an integral and routine part of health assessments globally.
Company Profile and Achievements
VentriJect's Seismofit® device represents a significant advancement in medical technology by enabling fast, accurate measurement of VO2 max without the physical exertion required by traditional methods. This has opened new possibilities in both clinical and fitness applications:
- 2018-2021: Development and commercialization of the Seismofit® device. Achieved CE-marking, ensuring its readiness for widespread medical use.
- Post-2021: The Seismofit® system has found applications in various European healthcare markets, integrating into preventative health strategies and sports science.
- Acknowledged by the American Heart Association and included as part of the cardiorespiratory fitness metrics.
- Global Recognition: Multiple awards and recognitions, including a second-place finish at the Healthcare Innovation World Cup, highlighting the device’s potential to revolutionize health assessments.
Current Operations and Market Position
VentriJect is currently focusing on expanding its geographical footprint beyond its European base into the expansive US market. The company’s strategic initiatives include:
- Leveraging its technological advances to penetrate markets with high demand for efficient and non-intrusive health monitoring technologies.
- Establishing partnerships with healthcare institutions to incorporate their devices into regular health assessment protocols.
- Continuous innovation and product enhancement driven by substantial feedback from clinical implementations.
- VentriJect’s device offers a competitive advantage by eliminating the need for exercise in cardiorespiratory fitness evaluations and significantly reducing the time required for tests to under three minutes.
Conclusion
VentriJect stands at the forefront of medical technology innovation with its Seismofit® system. By transforming how cardiorespiratory fitness is measured, it’s poised to make a significant impact on global health management practices. With further expansion plans and strategic market entries underway, VentriJect is set to enhance its role in both clinical and fitness contexts. The continued development and application of their technology promise a brighter, more accessible future for health assessments, aligning with increasing consumer and healthcare provider needs for efficient healthcare solutions.